替米沙坦对肥胖性高血压患者体脂、血脂及胰岛素抵抗的影响

Effects of telmisartan on body fat,serum lipids and insulin resistance in patients with obesity hypertension

目的探讨替米沙坦对肥胖性高血压患者体脂、血脂、胰岛素抵抗的影响。方法 BMI≥25 kg/m2的原发性高血压患者60例,随机分成观察组和对照组,并分别给予替米沙坦和硝苯地平缓释片干预,观察干预前后BP、BMI、腰臀比(W/H)、TC、LDL-C、TG、胰岛素抵抗指数(IRI)、高敏C反应蛋白(hsCRP)等指标变化。结果与干预前比较,干预后12、24周两组BP均下降(P<0.01),干预后24周观察组W/H、TGI、RI、hsCRP下降(P<0.01或P<0.05)。观察组IRI、hsCRP的变化与SBP、DBP、BMI、W/H、TG等呈直线相关。结论替米沙坦除良好的降压外,有一定的减轻腹型肥胖、控制TG和改善胰岛素抵抗的作用。

Objective To investigate the effects of telmisartan on serum lipids and insulin resistance in patients with obesity hypertension.Methods Sixty patients with hypertension and BMI≥25 kg/m2 were randomly divided into treatment group and control group（n=30） treated with telmisartan and nifedipine,respectively.The expression levels of BP,BMI,W/H,TG,TC,LDL-C,IRI and hsCRP were examined before and after treatment for 12 and 24 weeks.Results Compared with pre-treatment,the BP in both groups decreased significantly after treatment for 12 and 24 weeks（P0.01）.Simultaneously,the expression levels of W/H,TG,IRI,hsCRP were decreased significantly after 24 weeks in the treatment group（P0.01 or P0.05）.Correlation analysis proved that the expression levels of IRI,hsCRP were linearly related with SBP,DBP,BMI,W/H and TG.Conclusion Telmisartan can reduce BP and decrease the levels of W/H,TG,IRI with a certain extent.